All In Biotech

Drug Trial Radar · NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,400

Planned (sponsor's estimate)

Start

Jul 21, 2020

Primary completion

Jun 30, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Mar 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Undergo allogeneic HSCT

  • Asparaginase Erwinia chrysanthemiDrug

    Given IM or IV

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo BM aspiration

  • Bone Marrow BiopsyProcedure

    BM biopsy

  • Computed TomographyProcedure

    Undergo CT

  • CytarabineDrug

    Given IV or IT

  • Daunorubicin HydrochlorideDrug

    Given IV

  • Dexrazoxane HydrochlorideDrug

    Given IV

  • EtoposideDrug

    Given IV

  • Fludeoxyglucose F-18Other

    Undergo FDG-PET

  • Gemtuzumab OzogamicinDrug

    Given IV

  • Gilteritinib FumarateDrug

    Given PO/NG/G-tube

  • Liposome-encapsulated Daunorubicin-CytarabineDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • MethotrexateDrug

    Given IT

  • Mitoxantrone HydrochlorideDrug

    Given IV

  • Positron Emission TomographyProcedure

    Undergo FDG-PET

  • Questionnaire AdministrationOther

    Ancillary studies

  • Therapeutic HydrocortisoneDrug

    Given IT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: Up to 3 years

Locations

206 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Recruiting

  • USA Health Strada Patient Care Center

    Mobile, Alabama · Recruiting

  • Banner Children's at Desert

    Mesa, Arizona · Recruiting

  • Phoenix Childrens Hospital

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Kaiser Permanente Downey Medical Center

    Downey, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Mattel Children's Hospital UCLA

    Los Angeles, California · Recruiting

  • Valley Children's Hospital

    Madera, California · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Rady Children's Hospital - San Diego

    San Diego, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Santa Barbara Cottage Hospital

    Santa Barbara, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado · Recruiting

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Active not recruiting

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida · Recruiting

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida · Recruiting

  • Palms West Radiation Therapy

    Loxahatchee Groves, Florida · Active not recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Suspended

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Nemours Children's Hospital

    Orlando, Florida · Recruiting

Showing 40 of 206 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.